According to a new report Global Plasma Fractionation Market, published by KBV research, The Global Plasma Fractionation Market size is expected to reach $28.2 billion by 2027, rising at a market growth of 9.6% CAGR during the forecast period.
The Immunoglobulins market dominated the Global Plasma Fractionation Market by Product in 2020, growing at a CAGR of 9.4 % during the forecast period. The Albumin market is experiencing a CAGR of 9.2% during (2021 - 2027). Additionally, The Coagulation factor VIII market is expected to witness highest CAGR of 11.2% during (2021 - 2027).
The Private Sector market dominated the Global Plasma Fractionation Market by Sector in 2020, and would continue to be a dominant market till 2027. The Public Sector market is expected to witness a CAGR of 10.4% during (2021 - 2027).
In North America, the US procured the maximum share of the plasma fractional market in 2020. This is owing to the increasing geriatric population and related diseases. The Alzheimer’s Association noted that approximately 5.8 million individuals in the United State are suffering from Alzheimer’s diseases in 2018. This disease is the sixth major cause of death in the United States and is more prevalent among people more than 65 years of age, as around 5.6 million patients fall in this age group. With the baby-boom generation arriving approximately 65 years of age, this number would reach 14 million, deteriorating the situation during the forecast period. In addition, key makers are aiming to expand their geographical presence in developing countries of APAC to exploiter the untapped opportunities. This, in turn, would support the growth of the regional plasma fractionation market.
Full Report: https://www.kbvresearch.com/plasma-fractionation-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Emergent BioSolutions, Inc., CSL Limited, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, LFB S.A, Biotest AG (Tiancheng International Investment Limited), Sanquin Blood Supply Foundation, and Bio Products Laboratory Limited.
By Product
By Sector
By Geography
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
